Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
rizzato
rizzato Jun. 2 at 2:22 PM
$EYPT ridiculous no volume -6% good job shorters
0 · Reply
rizzato
rizzato Jun. 1 at 3:01 PM
$EYPT unfortunately if we do not have any real news from the company shorters are jocking with us and with no volume we drop back
1 · Reply
twib
twib May. 29 at 6:23 PM
$EYPT Alright, movin the right directon anyway.
1 · Reply
rizzato
rizzato May. 28 at 9:24 AM
$EYPT I think the situation now is clear , all the investor are waiting to get concrete news about the FDA and as soon as we will get them , if they will be positive, we will see a green way to the up very fast
3 · Reply
shawn45
shawn45 May. 26 at 11:44 PM
$OTLK $EYPT EYEPOINT stock, when the company was received 1st US FDA Approval for different regular eye medicine, stock skyrocketed from 97 cents to 16-22 bucks. OTLK something big brewing. POTENTIAL BLOCKBUSTER ophthalmic formulation 1st EYE Medicine going for an US FDA approval with FDDR resolution 1. OTLK - JULY 2026 US FDA APPROVAL 100% GUARANTEED now 2. AQST - MARCH/APRIL 2027 US FDA Approval (Q3 October US FDA resubmission)
2 · Reply
MarketBeat
MarketBeat May. 26 at 4:05 PM
https://marketbeat.com/a/8675794/ $EYPT EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
0 · Reply
rizzato
rizzato May. 26 at 3:08 PM
$EYPT EyePoint, Inc. (EYPT) Stifel 2026 Virtual Ophthalmology Forum May 26, 2026 9:00 am EDT NOT BAD AT ALL
0 · Reply
Tmoney85285
Tmoney85285 May. 22 at 2:57 PM
$OCUL you should care. while you guys were toiling away, $EYPT has closed the MC gap to the tune of 400M. now, instead of it being a 1 to 1.1B MC difference, it's sub 700K and closing. but, what do i know?
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 20 at 9:27 PM
$EYPT Great piece that accurately captures EYPT's current position. So if you want to refresh your understanding of EYPT or learn about EYPT for the first time, this is essential reading. https://everyticker.com/quote/EYPT/analysis/eyepoint-s-duravyu-gambit-a-6-month-injection-for-a-6-year-runway-challenge-nasdaq-eypt
1 · Reply
Poet5
Poet5 May. 18 at 1:27 PM
$EYPT This 12.40 going down to 10.00 is Absurd!
0 · Reply
Latest News on EYPT
EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 9:00 AM EDT - 9 days ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum


EyePoint reports Q1 EPS (99c), consensus (81c)

2026-05-07T07:35:29.000Z - 4 weeks ago

EyePoint reports Q1 EPS (99c), consensus (81c)


EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 weeks ago

EyePoint Earnings Call Transcript: Q1 2026


EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 weeks ago

EyePoint Earnings release: Q1 2026


EyePoint Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 weeks ago

EyePoint Quarterly report: Q1 2026


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

EyePoint Proxy statement: Proxy filing


EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

EyePoint Proxy statement: Proxy filing


EyePoint Slides: Corporate presentation

Apr 23, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Slides: Corporate presentation


EyePoint price target raised to $35 from $31 at Citi

2026-03-09T10:55:47.000Z - 3 months ago

EyePoint price target raised to $35 from $31 at Citi


EyePoint price target raised to $30 from $23 at H.C. Wainwright

2026-03-05T11:11:09.000Z - 3 months ago

EyePoint price target raised to $30 from $23 at H.C. Wainwright


EyePoint price target raised to $29 from $27 at Chardan

2026-03-04T19:55:31.000Z - 3 months ago

EyePoint price target raised to $29 from $27 at Chardan


EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 3 months ago

EyePoint Earnings Call Transcript: Q4 2025


EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 3 months ago

EyePoint Annual report: Q4 2025


EyePoint Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 3 months ago

EyePoint Earnings release: Q4 2025


EyePoint reports Q4 EPS (81c), consensus (75c)

2026-03-04T12:10:17.000Z - 3 months ago

EyePoint reports Q4 EPS (81c), consensus (75c)


EyePoint expects cash to fund operations into Q4 2027

2026-03-04T12:09:56.000Z - 3 months ago

EyePoint expects cash to fund operations into Q4 2027


EyePoint Slides: Investor presentation

Mar 2, 2026, 7:00 AM EST - 3 months ago

EyePoint Slides: Investor presentation


EyePoint price target raised to $36 from $33 at Mizuho

2026-02-19T12:28:49.000Z - 3 months ago

EyePoint price target raised to $36 from $33 at Mizuho


EyePoint appoints Campbell as Chief Commercial Officer

2026-02-18T12:05:24.000Z - 3 months ago

EyePoint appoints Campbell as Chief Commercial Officer


EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 3 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer


EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 5 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 5 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference


EyePoint Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

EyePoint Slides: Investor presentation


EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 7 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference


EyePoint Slides: FY 2025

Nov 12, 2025, 10:40 AM EST - 7 months ago

EyePoint Slides: FY 2025


EyePoint selloff brings buying opportunity, says Mizuho

2025-11-11T12:20:18.000Z - 7 months ago

EyePoint selloff brings buying opportunity, says Mizuho


EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

EyePoint Earnings Call Transcript: Q3 2025


EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

EyePoint Quarterly report: Q3 2025


EyePoint Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

EyePoint Earnings release: Q3 2025


EyePoint reports Q3 EPS (85c), consensus (77c)

2025-11-05T12:11:53.000Z - 7 months ago

EyePoint reports Q3 EPS (85c), consensus (77c)


EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 8 months ago

EyePoint Announces Pricing of Public Offering


EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 8 months ago

EyePoint Announces Proposed Public Offering of Common Stock


EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 9 months ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025


EyePoint Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 2:30 PM EDT - 9 months ago

EyePoint Transcript: Citi's Biopharma Back to School Conference


EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

EyePoint Earnings Call Transcript: Q2 2025


EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

EyePoint Quarterly report: Q2 2025


EyePoint Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

EyePoint Earnings release: Q2 2025


EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum


EyePoint Slides: Investor Presentation

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation


EyePoint Proxy statement: Proxy Filing

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025


EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025


EyePoint Earnings release: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024


EyePoint Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Annual report: Q4 2024


EyePoint Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings release: Q4 2024


EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference


EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference


EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update


EyePoint Press release: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Press release: Status Update


EyePoint Slides: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Slides: Status Update


EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference


EyePoint Slides: FY 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Slides: FY 2025


EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024


EyePoint Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Quarterly report: Q3 2024


EyePoint Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Earnings release: Q3 2024


EyePoint Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 2:30 PM EDT - 1 year ago

EyePoint Transcript: UBS Virtual Ophthalmology Day


EyePoint Registration statement: Registration Filing

Aug 8, 2024, 8:00 AM EDT - 1 year ago

EyePoint Registration statement: Registration Filing


EyePoint Quarterly report: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 1 year ago

EyePoint Quarterly report: Q2 2024


EyePoint Earnings release: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 1 year ago

EyePoint Earnings release: Q2 2024


EyePoint Slides: Investor Presentation

Jul 9, 2024, 6:00 AM EDT - 2 years ago

EyePoint Slides: Investor Presentation


EyePoint Transcript: R&D Day 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: R&D Day 2024


EyePoint Press release: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: FY 2024


EyePoint Slides: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: FY 2024


EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024


EyePoint Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Quarterly report: Q1 2024


EyePoint Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Earnings release: Q1 2024


EyePoint Transcript: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: Study Update


EyePoint Press release: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: Study Update


EyePoint Slides: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: Study Update


EyePoint Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Proxy statement: Proxy Filing


EyePoint Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Proxy statement: Proxy Filing


EyePoint Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Earnings Call Transcript: Q4 2023


EyePoint Annual report: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Annual report: Q4 2023


EyePoint Earnings release: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Earnings release: Q4 2023


rizzato
rizzato Jun. 2 at 2:22 PM
$EYPT ridiculous no volume -6% good job shorters
0 · Reply
rizzato
rizzato Jun. 1 at 3:01 PM
$EYPT unfortunately if we do not have any real news from the company shorters are jocking with us and with no volume we drop back
1 · Reply
twib
twib May. 29 at 6:23 PM
$EYPT Alright, movin the right directon anyway.
1 · Reply
rizzato
rizzato May. 28 at 9:24 AM
$EYPT I think the situation now is clear , all the investor are waiting to get concrete news about the FDA and as soon as we will get them , if they will be positive, we will see a green way to the up very fast
3 · Reply
shawn45
shawn45 May. 26 at 11:44 PM
$OTLK $EYPT EYEPOINT stock, when the company was received 1st US FDA Approval for different regular eye medicine, stock skyrocketed from 97 cents to 16-22 bucks. OTLK something big brewing. POTENTIAL BLOCKBUSTER ophthalmic formulation 1st EYE Medicine going for an US FDA approval with FDDR resolution 1. OTLK - JULY 2026 US FDA APPROVAL 100% GUARANTEED now 2. AQST - MARCH/APRIL 2027 US FDA Approval (Q3 October US FDA resubmission)
2 · Reply
MarketBeat
MarketBeat May. 26 at 4:05 PM
https://marketbeat.com/a/8675794/ $EYPT EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
0 · Reply
rizzato
rizzato May. 26 at 3:08 PM
$EYPT EyePoint, Inc. (EYPT) Stifel 2026 Virtual Ophthalmology Forum May 26, 2026 9:00 am EDT NOT BAD AT ALL
0 · Reply
Tmoney85285
Tmoney85285 May. 22 at 2:57 PM
$OCUL you should care. while you guys were toiling away, $EYPT has closed the MC gap to the tune of 400M. now, instead of it being a 1 to 1.1B MC difference, it's sub 700K and closing. but, what do i know?
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 20 at 9:27 PM
$EYPT Great piece that accurately captures EYPT's current position. So if you want to refresh your understanding of EYPT or learn about EYPT for the first time, this is essential reading. https://everyticker.com/quote/EYPT/analysis/eyepoint-s-duravyu-gambit-a-6-month-injection-for-a-6-year-runway-challenge-nasdaq-eypt
1 · Reply
Poet5
Poet5 May. 18 at 1:27 PM
$EYPT This 12.40 going down to 10.00 is Absurd!
0 · Reply
rizzato
rizzato May. 15 at 7:46 PM
$EYPT -6% with 300k pcs ridiculous
0 · Reply
KimboIce
KimboIce May. 11 at 8:25 PM
0 · Reply
Poet5
Poet5 May. 11 at 3:33 PM
$EYPT Watch for a secondary offering after close of today, hence the high volune.
1 · Reply
KimboIce
KimboIce May. 11 at 2:44 PM
$EYPT the run up starts today
3 · Reply
Quantumup
Quantumup May. 8 at 7:24 PM
BofA reiterated Top Pick $OCUL Buy; $27 in its SMID cap investor's guide to Health Care (including top stock ideas) $EYPT REGN FDMT RHHBY KOD $SRZN Here's what BofA said in its note: https://x.com/Quantumup1/status/2052831264231526811?s=20
0 · Reply
Quantumup
Quantumup May. 7 at 12:36 PM
Guggenheim reiterated its Top Pick $EYPT Buy; $68 $OCUL $SRZN REGN RHHBY FDMT KOD Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2052365956958109965?s=20
1 · Reply
brucino
brucino May. 7 at 11:37 AM
$EYPT It's only being kept alive because of optimistic expectations about the trials, because if you look at the budget, there's a lot to worry about... But we'll have to see what price level we'll be at when the clinical data are released. Good luck to us 🤞🤞💪💪
1 · Reply
Jjarnold44
Jjarnold44 May. 6 at 7:26 PM
$EYPT Didn't one of you beat me up saying you would need to raise this year? Welp, here ya go!
1 · Reply
Poet5
Poet5 May. 6 at 6:44 PM
$EYPT Yeah! let ot sink to 10-12 range. what bullshit!
1 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 1:47 PM
$EYPT Share Price: $13.77 Contract Selected: Aug 21, 2026 $15 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.16 – $6.30 Potential Upside: 52% ROI Time to Expiration: 106 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
brucino
brucino May. 6 at 11:17 AM
$EYPT today will be a disaster😡😡
2 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:14 AM
$EYPT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.99 down -52.31% YoY • Reported revenue of $0.7M down -97.15% YoY • EyePoint expects its cash, cash equivalents, and marketable securities of $223M as of March 31, 2026, will fund operations into Q4 2027, extending beyond key Phase 3 wet AMD program milestones.
0 · Reply